Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, presented data showing the potential of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower intra-ocular pressure (IOP) in human subjects. The data were presented as part of Special Session, entitled “The Role of the Tie2 Pathway in Ocular Disease,” at The Association for Research in Vi